Pyxis Oncology Inc. (PYXS) has emerged as a clinical-stage biopharmaceutical company to watch, with a clear focus on developing innovative therapeutics for difficult-to-treat cancers.
Its lead candidate, micvotabart pelidotin (MICVO), represents a first-in-concept antibody drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix that is largely absent in normal adult tissues. By leveraging this unique target, Pyxis aims to deliver a therapy capable of reshaping treatment outcomes for patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com